Exelixis, Inc.
EXEL
Pozycja w akcjach
#1431
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Cena akcji
$61.84
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$15.54B
Zmiana (1 dzień)
-1.58%
Zmiana (1 rok)
57.55%
Kraj
US
Handel Exelixis, Inc. (EXEL)
Kategoria
Healthcare
Marża operacyjna dla Exelixis, Inc. (EXEL)
Marża operacyjna na dzień October 2026 TTM: 39.88%
Według najnowszych raportów finansowych i ceny akcji Exelixis, Inc., bieżąca marża operacyjna (TTM) wynosi 39.88%. Na koniec 2025 wynosiła 27.88%.
Historia marży operacyjnej dla Exelixis, Inc. od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 39.88% | 43.04% |
| 2025 | 27.88% | 198.50% |
| 2023 | 9.34% | -25.34% |
| 2022 | 12.51% | -37.39% |
| 2021 | 19.98% | -47.67% |
| 2020 | 38.18% | -25.72% |
| 2018 | 51.40% | 40.17% |
| 2017 | 36.67% | -349.63% |
| 2016 | -14.69% | -98.36% |
| 2014 | -893.86% | 39.55% |
| 2013 | -640.54% | 148.24% |
| 2012 | -258.03% | -934.78% |
| 2011 | 30.91% | -162.58% |
| 2010 | -49.39% | -67.54% |
| 2009 | -152.14% | 9.93% |
| 2007 | -138.40% | 7.74% |
| 2006 | -128.46% | 3.81% |
| 2005 | -123.74% | -51.62% |
| 2004 | -255.79% | 36.95% |
| 2003 | -186.77% | -5.74% |
| 2002 | -198.15% | 7.88% |
| 2001 | -183.67% | 6.09% |
| 2000 | -173.12% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -99.03% |
US
|
|
| -149.01% | -103.74% |
US
|
|
| 25.57% | -99.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.28% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.